Harrow, Inc. (HROW) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-03-02
How it makes money
Harrow earns revenue by marketing and selling branded ophthalmic pharmaceutical products and compounded formulations to eyecare professionals and patients.
Harrow generates revenue by acquiring, licensing, and internally developing commercial rights to FDA-approved ophthalmic products and compounded formulations. Its portfolio includes therapies for dry eye disease, glaucoma, retinal diseases, and post-operative inflammation, such as VEVYE, IHEEZO, and TRIESENCE. Profitability depends heavily on the company's ability to successfully commercialize these branded drugs, expand sales territories, optimize pricing, and secure favorable reimbursement coverage from government and commercial third-party payors.
What protects it: the moat
Management claims that patent protection, regulatory approvals, and proprietary drug formulations defend its portfolio from direct competitors.
The company relies on securing and maintaining patents, regulatory exclusivity, and proprietary technologies like APNT nanoparticle formulation technology and water-free vehicles. However, the filings indicate that maintaining these barriers requires ongoing legal and regulatory efforts, and management asserts that competition from biosimilars or alternative drug candidates could emerge.
What growth costs
Growth requires substantial ongoing investments in commercial sales force expansion, research and development, and business acquisitions.
The company incurs significant expenses related to commercialization activities, research and development for drug candidates, and pharmaceutical compounding operations. Recent growth initiatives include expanding the U.S. sales team for VEVYE and increasing sales resources for IHEEZO and TRIESENCE, alongside acquisition-related cash payments and contingent milestones.
What could damage it
If third-party payors deny coverage or reduce reimbursement rates for Harrow products, customer adoption could fall and permanently impair earnings.
Harrow depends on favorable coverage and reimbursement decisions from government and commercial third-party payors. If these payors restrict access, reduce reimbursement amounts, or refuse to grant necessary codes, eyecare professionals and patients may shift to alternative therapies, directly depressing revenue and damaging operating results.
About Harrow, Inc.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.